Daiwa Securities Group’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-1,579
Closed -$23K – 1358
2022
Q1
$23K Buy
1,579
+496
+46% +$14.1K ﹤0.01% 1107
2021
Q4
$57K Buy
1,083
+734
+210% +$40.9K ﹤0.01% 1083
2021
Q3
$20K Buy
+349
New +$22.8K ﹤0.01% 1104
2019
Q3
– Sell
-800
Closed -$183K – 1180
2019
Q2
$183K Buy
+800
New +$156K ﹤0.01% 894
2018
Q3
– Sell
-3,500
Closed -$774K – 1167
2018
Q2
$780K Buy
3,500
+1,772
+103% +$396K 0.01% 538
2018
Q1
$394K Buy
+1,728
New +$454K ﹤0.01% 689

Other funds holding AXDX

Daiwa Securities Group's AXDX Position: Q2 2022 in Review

Daiwa Securities Group sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 1,579 shares — an estimated $23K sold.

Daiwa Securities Group first reported a position in AXDX in Q1 2018 and held it in 6 quarters. The position peaked at $780K in Q2 2018. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Daiwa Securities Group reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 1,579 Accelerate Diagnostics shares in Q2 2022, an estimated $23K.
  • Daiwa Securities Group first reported a position in Accelerate Diagnostics in Q1 2018 and held it in 6 quarters.
  • Daiwa Securities Group's Accelerate Diagnostics position peaked at $780K in Q2 2018.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Daiwa Securities Group's 13F filing for Q2 2022, filed 9 Aug 2022.